What is Seqster?
Seqster operates as a sophisticated SaaS-based healthcare technology provider, specializing in the aggregation of longitudinal health data. By integrating electronic health records (EHR), genomic profiles, and personal health device data, the platform facilitates a comprehensive, person-centric view of patient health. This interoperability is critical for healthcare enterprises, including pharmaceutical firms, payers, and life insurance providers, who require high-fidelity data to drive clinical efficiency and personalized care strategies. Seqster effectively transforms fragmented information into a unified, longitudinal profile, establishing itself as a foundational layer in the modern digital health ecosystem.
How much funding has Seqster raised?
Seqster has raised a total of $12M across 1 funding round:
Series A
$12M
Series A (2021): $12M with participation from OmniHealth Holdings, Ann Wojcicki, and Takeda Digital Ventures
Key Investors in Seqster
OmniHealth Holdings
A specialized investment firm focused on scaling innovative healthcare infrastructure and digital health platforms.
Ann Wojcicki
A prominent figure in the genomics industry, known for supporting ventures that prioritize personal health data accessibility and genetic research.
Takeda Digital Ventures
The corporate venture arm of a global pharmaceutical leader, dedicated to investing in digital health technologies that enhance drug development and patient outcomes.
What's next for Seqster?
With this major enterprise-level funding, Seqster is poised to scale its operational infrastructure and expand its footprint within the life sciences and insurance sectors. The strategic deployment of this capital will likely focus on enhancing the platform's data processing capabilities and deepening integrations with US-based healthcare providers. As the industry shifts toward value-based care, Seqster's ability to provide real-time, matched health data will be instrumental in supporting clinical trials, risk assessment, and patient engagement initiatives. The company is now positioned to transition from its current scaling phase toward broader market penetration, leveraging its unique technological moat to redefine how healthcare organizations interact with patient-generated data.
See full Seqster company page
